CCL21 was used in a syngeneic 4T1.2 mouse breast model to attract ILC3s to primary tumors, which then induces tumor stromal cells to secrete CXCL13, and then results in lymphotoxin and activates receptor of NF-κB ligands, which stimulate tumor cell migration and lymphangiogenesis [121]. Here, CXCL13 is linked to neoplasm.